We thank Ivica Ratosa for her insightful commentary about the discrepancy in the cut-off of hormone-positive breast cancer. Indeed, according to the 2020 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP), breast cancers with\<1% of ER or PR expression should be considered hormone receptor--negative tumors \[[@bib1]\]. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1%--10% of cells staining ER positive \[[@bib1]\]. Previous studies suggest that breast cancers with 1%--10% of ER expression had similar molecular features and clinical prognoses to those of breast cancers with\<1% of ER expression \[[@bib2]\]. The St. Gallen International Expert Consensus 2019 reported that there is no ideal cutoff value between 1 or 10%, that is why this situation should be discussed in the tumor board and with the patient, taking into account other factors such as the patient's age and additional prognostic factors \[[@bib3]\]. In our study, only 1.3% and 4.8% had respectively 1--9% of ER and PR expression on surgical samples, probably not impacting global results.

Regarding her second remark, the proportion of patients with ER-negative invasive carcinoma (T \> 1 cm or N+) who received adjuvant chemotherapy was calculating after exclusion of patients who received neoadjuvant chemotherapy.
